We work only with FDA-registered tissue banks. The connective tissue allografts we use are derived from donated human umbilical cord (Wharton's jelly) and processed to preserve the structural matrix — for cushioning and structural support, homologous use only.
In the U.S., there are limited legal pathways to obtain donated umbilical cord tissue — and they run through FDA-registered facilities. We partner with registered labs for the products we use, including Vitti Labs and Regenative Labs.
An FDA-registered tissue bank, AATB-accredited and cGMP-certified, following GTP and WHO protocols. Provides the WJ-PURE+ and EV-PURE+ allografts described below.
An FDA-registered manufacturer of cryopreserved Wharton's jelly allografts processed to maintain the naturally occurring extracellular matrix and structural proteins.
Product names and trademarks belong to their respective owners and are referenced here to describe the materials we use. Vitti Labs and Regenative Labs products are FDA-registered, not FDA-approved, and are intended for use by medical professionals.
A short animated explainer covering what Wharton’s jelly is, where it comes from, and how connective tissue allografts are intended to provide cushioning and structural support. Educational only — not medical advice.
An informational overview of Wharton’s jelly — what it is, how it is donated and processed, and how allografts are intended to provide cushioning and structural support. Educational only — not medical advice.
Video disclaimer: The videos above are the proprietary property of Regenative Labs and are reproduced here with permission for educational purposes only. All rights, trademarks, and content remain those of Regenative Labs. They are not medical advice, do not constitute a treatment recommendation, and are not intended to diagnose, treat, cure, or prevent any disease. Connective tissue allografts are FDA-registered, not FDA-approved, and are intended for homologous use to provide cushioning and structural support. Individual results vary and are not guaranteed.
Both are minimally manipulated, bio-ethical human umbilical cord allografts manufactured under GTP, cGMP, AATB and FDA HCT/P 361 guidelines. Both are DSMO-free, and the proprietary process is free of harmful enzymes and chemicals to preserve integrity.
A Wharton's jelly connective tissue allograft for homologous use in clinical settings, containing nonconduit structural tissue.
A minimally manipulated umbilical cord-harvested allograft containing nonconduit structural tissue, aseptically processed and packaged.
These products may contain live cells but are not dependent on the metabolic activity of living cells for their primary function. They meet the criteria of 21 CFR 1271.10 and are regulated under 21 CFR 1271 and Section 361 of the PHS Act. They are not approved by the FDA and are intended for use by medical professionals only.
Cryopreserved Wharton’s jelly (human umbilical cord) allografts, rich in cytokines, growth factors, and scaffolding proteins. Both are regulated as HCT/Ps under 21 CFR Part 1271 and Section 361 of the Public Health Service Act, and are ethically derived from healthy, consenting mothers following full-term, planned Cesarean deliveries — never from an embryo or fetus.
The same product as CryoText™ Pro at double the concentration. It was designed primarily for spinal cases, where providers were previously using two CryoText™ Pro applications.
A cryopreserved umbilical cord tissue allograft intended to supplement missing or damaged connective tissue in homologous applications, with high concentrations of hyaluronic acid and growth factors.
These products are intended for homologous use to supplement missing or damaged connective tissue, as described in 21 CFR 1271.10(a). They are FDA-registered, not FDA-approved, and are not intended to diagnose, treat, cure, or prevent any disease. Individual patient results may vary as not all outcomes are the same. Product names and specifications are the property of Regenative Labs.
Before any allograft is used, the donation moves through a regulated chain of screening and testing. A few of the safeguards built in:
Tissue is donated following healthy, full-term deliveries with the mother's informed consent.
Mothers and cord tissue are thoroughly screened for infectious disease, sterility and endotoxins.
Handling meets the standards of the American Association of Tissue Banks.
Processing takes place in a CLIA-certified laboratory under the Clinical Laboratory Improvement Amendments of 1988.
The allografts we use are human cells, tissues, and cellular/tissue-based products (HCT/Ps), regulated under Section 361 of the Public Health Service Act and 21 CFR Part 1271. To qualify for the 361 pathway, a product must meet all four criteria below.
Processing doesn't alter the tissue's original relevant characteristics for reconstruction, repair or replacement.
It performs the same basic function in the recipient as in the donor — here, cushioning and structural support.
Combined only with water, crystalloids, or a permitted sterilizing, preserving or storage agent.
Not dependent on the metabolic activity of living cells for its primary function, and not marketed to treat disease.
In the donor, Wharton's jelly cushions and structurally supports the umbilical cord vessels. In the recipient, it does the same basic structural job — cushioning and support — at the site where it's applied.
People explore connective tissue allografts for different reasons. Framed honestly, here's what this option is — and isn't — built to do. None of this is a promise of results, and a licensed provider will tell you if it isn't a fit.
Supplements missing or damaged connective tissue, adding structural cushioning and support at the site of a defect.
Placed exactly where support is needed and intended to stay there — roughly 98% remains in the treated area. It isn't systemic.
A shallow, ultrasound-guided application rather than surgery. Some patients have reported little to no downtime.
Many people want to learn about non-surgical options before considering bigger steps. This is one option to understand — with no obligation.
Connective tissue allografts are intended to provide cushioning and structural support for homologous use only. They are FDA-registered, not FDA-approved, and are not intended to diagnose, treat, cure, or prevent any disease, to reduce inflammation, or to avoid surgery. Individual results vary and are not guaranteed; not all outcomes are the same, and all medical procedures carry potential risks and side effects. See our full disclosures.
The materials we use are manufactured and studied by our partner labs. Explore their work and standards directly:
These links lead to third-party partner websites (Vitti Labs and Regenative Labs). Movera Wellness Institute is not responsible for content on external sites; trademarks belong to their respective owners.
Reserve a complimentary consultation, or attend a free seminar to learn how connective tissue allografts provide cushioning and structural support.
